Figure 4

Incremental cost-effectiveness (£/QALY) of neonatal screening for cystic fibrosis compared with no screening, assuming different cost discount rates and assumed effects of preventive therapy.
Incremental cost-effectiveness (£/QALY) of neonatal screening for cystic fibrosis compared with no screening, assuming different cost discount rates and assumed effects of preventive therapy.